Literature DB >> 9512553

Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.

N Bardeesy1, J Pelletier.   

Abstract

The Wilms' tumour suppressor gene (wt1) is mutated in a subset of patients with Wilms' tumour and has a critical role in urogenital development. wt1 encodes a zinc finger transcription factor which regulates expression of several genes involved in cellular proliferation and differentiation. Although a number of studies have characterized the DNA binding properties of the WT1 protein, recent evidence has suggested that WT1 may also have a role in RNA metabolism. We have used an RNA selection method to identify WT1 binding ligands from a random RNA pool. Three groups of RNA ligands specifically recognized by WT1 were identified. Mutational analysis pinpointed ribonucleotide sequences critical for binding. Analysis of truncated WT1 proteins demonstrated that three of four zinc fingers were necessary for RNA-protein interaction. The naturally occurring WT1 isoforms with insertion of lysine, threonine and serine between zinc fingers three and four were unable to bind the selected RNAs. The selected RNA ligands competed with the cognate WT1 DNA binding site for complex formation with WT1. Our findings suggest potential cellular RNA target sequences for WT1 and provide tools for studying the structural and functional properties of this tumour suppressor protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512553      PMCID: PMC147468          DOI: 10.1093/nar/26.7.1784

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  58 in total

Review 1.  The WT1 Wilms' tumor suppressor gene: how much do we really know?

Authors:  J C Reddy; J D Licht
Journal:  Biochim Biophys Acta       Date:  1996-05-16

2.  In vitro RNA selection identifies RNA ligands that specifically bind to eukaryotic translation initiation factor 4B: the role of the RNA remotif.

Authors:  N Methot; G Pickett; J D Keene; N Sonenberg
Journal:  RNA       Date:  1996-01       Impact factor: 4.942

3.  A non-AUG translational initiation event generates novel WT1 isoforms.

Authors:  W Bruening; J Pelletier
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

4.  The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54nrb.

Authors:  M Hallier; A Tavitian; F Moreau-Gachelin
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

5.  Truncated WT1 mutants alter the subnuclear localization of the wild-type protein.

Authors:  C Englert; M Vidal; S Maheswaran; Y Ge; R M Ezzell; K J Isselbacher; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

6.  An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling.

Authors:  D Kennedy; T Ramsdale; J Mattick; M Little
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

7.  RNA binding by the Wilms tumor suppressor zinc finger proteins.

Authors:  A Caricasole; A Duarte; S H Larsson; N D Hastie; M Little; G Holmes; I Todorov; A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein.

Authors:  E Karnieli; H Werner; F J Rauscher; L E Benjamin; D LeRoith
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

9.  An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation.

Authors:  N D Perkins; A B Agranoff; E Pascal; G J Nabel
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

10.  The evolution of WT1 sequence and expression pattern in the vertebrates.

Authors:  J Kent; A M Coriat; P T Sharpe; N D Hastie; V van Heyningen
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

View more
  21 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 2.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

3.  Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.

Authors:  Kylie Graham; Wenliang Li; Bryan R G Williams; Gail Fraizer
Journal:  Gene Expr       Date:  2006

4.  Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells.

Authors:  Kyue Yim Lee; Hyungu Kang; Sung Ho Ryu; Dong Soo Lee; Jung Hwan Lee; Soonhag Kim
Journal:  J Biomed Biotechnol       Date:  2010-03-01

5.  The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.

Authors:  Yeou-cherng Bor; Jennifer Swartz; Avril Morrison; David Rekosh; Michael Ladomery; Marie-Louise Hammarskjöld
Journal:  Genes Dev       Date:  2006-05-31       Impact factor: 11.361

6.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

7.  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.

Authors:  Maike Busch; Heinrich Schwindt; Artur Brandt; Manfred Beier; Nicole Görldt; Paul Romaniuk; Eneda Toska; Stefan Roberts; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

8.  High-throughput binding analysis determines the binding specificity of ASF/SF2 on alternatively spliced human pre-mRNAs.

Authors:  Brian Chang; J Levin; William A Thompson; William G Fairbrother
Journal:  Comb Chem High Throughput Screen       Date:  2010-03       Impact factor: 1.339

9.  RNA Binding by the KTS Splice Variants of Wilms' Tumor Suppressor Protein WT1.

Authors:  Tadateru Nishikawa; Jonathan M Wojciak; H Jane Dyson; Peter E Wright
Journal:  Biochemistry       Date:  2020-09-29       Impact factor: 3.162

10.  Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Authors:  Takuya Osada; Christopher Y Woo; Matthew McKinney; Xiao Yi Yang; Gangjun Lei; Heather G Labreche; Zachary C Hartman; Donna Niedzwiecki; Nelson Chao; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.